Mutanome

Genocea Presents Promising Long-term Results from GEN-009 Neoantigen Vaccine Phase 1 Trial at ASCO 2021

Retrieved on: 
Friday, June 4, 2021
Branches of biology, Medical specialties, Biology, Biotechnology, Vaccination, Applied genetics, Genomics, Medical genetics, Antigen, Vaccine, Individualized cancer immunotherapy, Mutanome

The poster is available for on-demand viewing on the ASCO website and also posted to the Scientific Resources section of the Genocea website here .

Key Points: 
  • The poster is available for on-demand viewing on the ASCO website and also posted to the Scientific Resources section of the Genocea website here .
  • Long-term results demonstrate that GEN-009 continues to generate broad immune responses against neoantigens that can lead to sustained clinical responses.
  • Six of the eight patients continue without recurrence with a median follow up of 25 months post start of the vaccination.
  • Notably, as previously reported, GEN-009 elicited T cell immune responses to 99% of the ATLAS-selected neoantigens, the highest seen across neoantigen vaccine programs.

Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics' Ancer Platform

Retrieved on: 
Thursday, May 13, 2021
Branches of biology, Medical specialties, Clinical medicine, Vaccines, Cancer vaccines, Genomics, Applied genetics, Biotechnology, Immunogenicity, Mutanome, Epitope, Antigen

b'PROVIDENCE, R.I., May 13, 2021 /PRNewswire/ -- EpiVax Therapeutics, Inc. ("EVT") announces the publication "Multistep screening of neoantigens\' HLA and TCRinterfaces improves prediction of survival" in Scientific Reports.

Key Points: 
  • b'PROVIDENCE, R.I., May 13, 2021 /PRNewswire/ -- EpiVax Therapeutics, Inc. ("EVT") announces the publication "Multistep screening of neoantigens\' HLA and TCRinterfaces improves prediction of survival" in Scientific Reports.
  • This study demonstrates a superior method of survival analysis for cancer patients using EVT\'s Ancer platform.
  • EVT spun-off from EpiVax, Inc. in 2017 to apply EpiVax tools to clinical research.\nBuilt on validated in silico tools EpiMatrix and JanusMatrix , Ancer analyzesindividual cancer mutanomes to definethe presence of T cell epitopes likely to be immunogenic.
  • EVT\'s pipeline includes a COVID-19 vaccine and a personalized bladder cancer vaccine.\n'

Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics' Ancer Platform

Retrieved on: 
Thursday, May 13, 2021
Branches of biology, Medical specialties, Clinical medicine, Vaccines, Cancer vaccines, Genomics, Applied genetics, Biotechnology, Immunogenicity, Mutanome, Antigen, Cancer vaccine

b'PROVIDENCE, R.I., May 13, 2021 /PRNewswire/ -- EpiVax Therapeutics, Inc. ("EVT") announces the publication "Multistep screening of neoantigens\' HLA and TCRinterfaces improves prediction of survival" in Scientific Reports.

Key Points: 
  • b'PROVIDENCE, R.I., May 13, 2021 /PRNewswire/ -- EpiVax Therapeutics, Inc. ("EVT") announces the publication "Multistep screening of neoantigens\' HLA and TCRinterfaces improves prediction of survival" in Scientific Reports.
  • This study demonstrates a superior method of survival analysis for cancer patients using EVT\'s Ancer platform.
  • EVT spun-off from EpiVax, Inc. in 2017 to apply EpiVax tools to clinical research.\nEpiVax Therapeutics researchers develop improved method for cancer survival prediction.\nBuilt on validated in silico tools EpiMatrix and JanusMatrix , Ancer analyzesindividual cancer mutanomes to definethe presence of T cell epitopes likely to be immunogenic.
  • EVT\'s pipeline includes a COVID-19 vaccine and a personalized bladder cancer vaccine.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/improving-cancer-survival-predic...\n'

Transgene Presents Its Individualized Immunotherapy, TG4050, at The Annual Neoantigen Based Therapies Summit

Retrieved on: 
Thursday, November 5, 2020
Oncology, Health, Clinical trials, Research, Science, Biotechnology, Branches of biology, Medical specialties, Clinical medicine, Vaccines, Cancer vaccines, Vaccination, Genomics, Medical genetics, Cancer vaccine, Vaccine, Individualized cancer immunotherapy, Mutanome

TG4050 is an individualized cancer vaccine based on our myvac technology that has the ability to elicit an immune response against up to 30 patient-specific tumor neoantigens.

Key Points: 
  • TG4050 is an individualized cancer vaccine based on our myvac technology that has the ability to elicit an immune response against up to 30 patient-specific tumor neoantigens.
  • The Neoantigen Based Therapies Summit is the leading end-to-end meeting dedicated to delivering the promise of accurate identification, prediction, and validation of neoantigens to develop highly efficacious vaccines and cell therapies.
  • TG4050 is an individualized cancer vaccine based on the myvac platform; it is based on an optimized viral platform for cancer vaccination and integrates NECs artificial intelligence capabilities.
  • Transgene is sponsoring two Phase 1 trials that are expected to deliver a first proof of concept of this virus-based individualized approach.

Transgene and NEC Demonstrate High Accuracy of AI-based Neoantigen Prediction for the Design of Individualized Cancer Vaccine TG4050

Retrieved on: 
Friday, May 15, 2020
Branches of biology, Biology, Vaccination, Medical specialties, Biotechnology, Medical genetics, Cancer vaccines, Genomics, Cancer vaccine, Vaccine, Individualized cancer immunotherapy, Mutanome

To evaluate the accuracy of the prediction, samples from cancer patients were collected.

Key Points: 
  • To evaluate the accuracy of the prediction, samples from cancer patients were collected.
  • Title of the poster: Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
    The abstract can be downloaded on the AACR website.
  • This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) identified and selected by NEC's Neoantigen Prediction System.
  • For more information, visit NEC at https://www.nec.com.For additional information, please also visit NEC Laboratories Europe GmbH at: http://www.neclab.eu

Achilles Therapeutics announces formation of Scientific Advisory Board

Retrieved on: 
Wednesday, May 13, 2020
Medicine, Branches of biology, Immune system, Clinical medicine, Cancer treatments, Cancer vaccines, Checkpoint inhibitor, Immune checkpoint, Cancer, Mutanome, Cancer immunotherapy

The SAB will work closely with Achilles senior management team and Founders to advance the Companys pipeline of solid tumor cancer therapies.

Key Points: 
  • The SAB will work closely with Achilles senior management team and Founders to advance the Companys pipeline of solid tumor cancer therapies.
  • We are delighted to be working with world-renowned experts who bring deep scientific and medical expertise as we develop the next-generation of truly patient-specific clonal-neoantigen therapies that will harness the immune system to destroy cancer cells, said Dr Iraj Ali, CEO of Achilles Therapeutics.
  • Her research focuses on cancer immune therapies including novel immune checkpoint inhibitors and cancer vaccines to overcome immune tolerance to cancers.
  • Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell.

Achilles Therapeutics announces formation of Scientific Advisory Board

Retrieved on: 
Wednesday, May 13, 2020
Medicine, Branches of biology, Immune system, Clinical medicine, Cancer treatments, Cancer vaccines, Checkpoint inhibitor, Immune checkpoint, Cancer, Mutanome, Cancer immunotherapy

The SAB will work closely with Achilles senior management team and Founders to advance the Companys pipeline of solid tumor cancer therapies.

Key Points: 
  • The SAB will work closely with Achilles senior management team and Founders to advance the Companys pipeline of solid tumor cancer therapies.
  • We are delighted to be working with world-renowned experts who bring deep scientific and medical expertise as we develop the next-generation of truly patient-specific clonal-neoantigen therapies that will harness the immune system to destroy cancer cells, said Dr Iraj Ali, CEO of Achilles Therapeutics.
  • Her research focuses on cancer immune therapies including novel immune checkpoint inhibitors and cancer vaccines to overcome immune tolerance to cancers.
  • Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell.

Neoantigen-based Personalized Cancer Therapeutic Vaccines Competitive Landscape and Market Forecast 2035

Retrieved on: 
Thursday, April 23, 2020
Branches of biology, Medical specialties, Medicine, Cancer vaccines, Vaccines, Vaccination, Genomics, Medical genetics, Vaccine, Immunity, Individualized cancer immunotherapy, Mutanome

Neoantigen-based Personalized Cancer therapeutic Vaccines allows the immune system to recognize cancer cells as foreign, and therefore, get the immune system to attack the cancer cells.

Key Points: 
  • Neoantigen-based Personalized Cancer therapeutic Vaccines allows the immune system to recognize cancer cells as foreign, and therefore, get the immune system to attack the cancer cells.
  • Neoantigen-based Personalized Cancer therapeutic Vaccines are one way to utilize the body's immune system to fight cancer.
  • Click here to know more on Competitive Landscape of Neoantigen-based Personalized Cancer Therapeutic Vaccines.
  • The pipeline of Neoantigen-based Personalized Cancer therapeutic Vaccines appears to be very promising with availability of vaccines in different stages of development.

Neoantigen-based Personalized Cancer Therapeutic Vaccines Competitive Landscape and Market Forecast 2035

Retrieved on: 
Thursday, April 23, 2020
Branches of biology, Medical specialties, Medicine, Cancer vaccines, Vaccines, Vaccination, Genomics, Medical genetics, Vaccine, Immunity, Individualized cancer immunotherapy, Mutanome

Neoantigen-based Personalized Cancer therapeutic Vaccines allows the immune system to recognize cancer cells as foreign, and therefore, get the immune system to attack the cancer cells.

Key Points: 
  • Neoantigen-based Personalized Cancer therapeutic Vaccines allows the immune system to recognize cancer cells as foreign, and therefore, get the immune system to attack the cancer cells.
  • Neoantigen-based Personalized Cancer therapeutic Vaccines are one way to utilize the body's immune system to fight cancer.
  • Click here to know more on Competitive Landscape of Neoantigen-based Personalized Cancer Therapeutic Vaccines.
  • The pipeline of Neoantigen-based Personalized Cancer therapeutic Vaccines appears to be very promising with availability of vaccines in different stages of development.

Avidea Technologies Utilizes GenScript's Synthesized Neoantigen Peptides for Novel Personalized Cancer Vaccine

Retrieved on: 
Wednesday, January 15, 2020
Branches of biology, Biology, Medicine, Cancer vaccines, Vaccines, Vaccination, Peptide, Vaccine, Genomics, Mutanome, Individualized cancer immunotherapy

PISCATAWAY, N.J., Jan. 15, 2020 /PRNewswire/ -- GenScript , a world leading biotechnology company, announced its support today of Avidea Technologies' efforts to develop a groundbreaking peptide-based personalized cancer vaccine.

Key Points: 
  • PISCATAWAY, N.J., Jan. 15, 2020 /PRNewswire/ -- GenScript , a world leading biotechnology company, announced its support today of Avidea Technologies' efforts to develop a groundbreaking peptide-based personalized cancer vaccine.
  • Developing and validating SNP-7/8a as a personalized cancer vaccine required synthesis of hundreds of unique neoantigen peptides, which were successfully synthesized by Genscript in support of this work.
  • The publication is particularly timely as personalized cancer vaccines are garnering increasing attention among the scientific and medical community as important components to enabling precision immuno-oncology.
  • To support this work, GenScript synthesized hundreds of challenging neoantigen peptides that were selected to have a wide range of properties, including neoantigen peptides with extremes of net charge and hydrophobicity, which was instrumental to enabling Avidea and NIH scientists to validate the generalizability of the SNP-7/8a platform as a personalized cancer vaccine.